Clinical Trial Update: Immunogenicity and Safety of 2 Doses of Avian Influenza A (H5N1) Vaccine Administered 3 vs. 8 Weeks Apart [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating the immunogenicity and safety of two doses of an Avian influenza A (H5N1) vaccine given 3 or 8 weeks apart.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Avian Influenza

Drugs mentioned

• Avian influenza A (H5N1) vaccine

Snippet

Sponsor: Canadian Immunization Research Network | Conditions: H5N1 Influenza, H5N1 Virus | Phase 4 | Status: ACTIVE_NOT_RECRUITING